Post-operative Pain (POP) - Competitive Landscape

Post-operative Pain (POP) - Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in POP therapeutics.
  • In 2024, more than 34,000,000 incident cases of POP are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for POP.
  • Most marketed drugs for POP are enzyme inhibitors, followed by receptor agonists, by mechanism of action.
  • Phase III pipeline for POP is robust and includes 27 drugs, while pre-registration comprises four drugs.
  • Approximately 39.34% of the clinical trials initiated over the last 10 years for POP have been conducted in sites across Asia-Pacific.
  • Acquisitions were the most prevalent deal type in North America, Europe, and Asia-Pacific.
Scope

GlobalData’s POP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the POP market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global POP market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Report Scope
  • Abbreviations
  • Key Findings
  • Disease Overview
    • Disease Etiology
  • Epidemiology Overview
    • Epidemiology Overview - Incident Cases of POP in 2024 and 2028
  • Treatment Overview
    • Treatment Guidelines
    • Management Algorithm - Multimodal Pain Control in POP for Hand Surgery
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in POP
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drug Profile - Heron Therapeutics's Zynrelef
    • Marketed Drug Profile - Hyloris Pharmaceuticals's Combogesic
    • Marketed Drug Profile - Sino Biopharmaceutical's Kaifen
    • Marketed Drug Profile - Merck's Hetori
    • Marketed Drug Profile - Daiichi Sankyo's Loxonin
    • Marketed Drug Profile - Mundipharma's OxyNorm/Endain
    • Marketed Drug Profile - Rayner Intraocular Lenses's Omidria
    • Marketed Drug Profile - B. Braun Melsungen's Ameniflac
    • Marketed Drug Profile - Jiangsu Hengrui Medicine's Bupivacaine
    • Marketed Drug Profile - Innocoll Holding's Xaracoll
    • Marketed Drug Profile - DURECT Corp's Posimir
    • Marketed Drug Profile - Jiangsu Hengrui Medicine's Aisut
    • Marketed Drug Profile - Cristalia Produtos Quimicos Farmaceutico's Fentanest Bolsa
    • Marketed Drug Profile - Halex Istar Industria Farmaceutica's Axiflennid
    • Marketed Drug Profile - Juno Pharmaceutical/Halex Istar Industria Farmaceutica's Naproxen
    • Marketed Drug Profile - Johnson & Johnson's Dolormin Duro/Motrimax
    • Marketed Drug Profile - Trevena's Olinvyk
    • Marketed Drug Profile - Talphera's Zalviso
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Annual Cost of Therapy
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Late-Stage Pipeline Drugs in POP
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in POP
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in CNS & POP
  • Clinical Trials Assessment
    • Clinical Trials in POP - Historical Overview
    • Clinical Trials in POP - Overview by Phase
    • Clinical Trials in POP - Overview by Status
    • Clinical Trials in POP - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in POP - Trials with a Virtual Component
    • Clinical Trials in POP - Geographic Overview
    • Clinical Trials in POP - Single-Country and Multinational Trials by Region
    • Clinical Trials in POP - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in POP - Top 20 Commercial Sponsors with Breakdown by Phase
    • Clinical Trials in POP - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in POP - Top 20 Commercial Sponsors with Breakdown by Status
    • Clinical Trials in POP - Overview by Endpoint Status
    • Clinical Trials in POP - Overview by Race and Ethnicity
    • Clinical Trials in POP - Enrollment Data
    • Clinical Trials in POP - Overview of Sites by Geography
    • Clinical Trials in POP - Top 20 Countries for Trial Sites
    • Clinical Trials in POP - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for POP
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in POP by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in POP
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in POP
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in POP
  • Appendix
    • Methodology - Sales Forecasts
    • Methodology
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings